Showing 1711-1720 of 2050 results for "".
- Aura Biosciences Reports Data from Study of Belzupacap Sarotalocan Versus Plaque Radiotherapy for Early-Stage Choroidal Melanomahttps://modernod.com/news/aura-biosciences-reports-topline-data-from-a-retrospective-study-of-belzupacap-sarotalocan-versus-plaque-radiotherapy-for-the-treatment-of-patients-with-early-stage-choroidal-melanoma/2480928/Aura Biosciences reported results from a retrospective, matched case control study that assessed the visual acuity of patients following treatment with plaque radiotherapy compared with prospective data on visual acuity in subjects with early-stage choroidal melanoma treated with belzup
- OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Diseasehttps://modernod.com/news/olix-pharmaceuticals-subsidiary-mcurex-announces-mrna-technology-collaboration-with-toolgen-for-rare-eye-disease/2480920/OliX Pharmaceuticals, a\ developer of RNAi therapeutics, announced that the company’s subsidiary, mCureX Therapeutics, has recently signed a contract for joint research with ToolGen to advance the development of gene therapy for rare eye diseases, leveraging mCureX’s mRNA technol
- University of Wisconsin Eye Research Uncovers How Stem Cell Photoreceptors Reach Their Targetshttps://modernod.com/news/uw-eye-research-uncovers-how-stem-cell-photoreceptors-reach-their-targets/2480915/A new study reveals how photoreceptors grown from stem cells might extend biological wires, known as axons, to contact existing neurons. The finding has implications for future treatment of retinal diseases that cause blindness, including age-related macular degeneration (AMD) and rare disea
- Dopavision Appoints Mark S. Wuttke, PhD, as Chief Executive Officerhttps://modernod.com/news/dopavision-appoints-mark-s-wuttke-phd-as-chief-executive-officer/2480881/Dopavision announced that Mark S. Wuttke, PhD, has been appointed as the company´s Chief Executive Officer. He succeeds Dopavision´s co-founder and previous Managing Director Stefan Zundel, who will remain on Dopavision´s advisory board and continue to advise the company.</
- The Vision Council Releases Provider inSights Q1 2022 Reporthttps://modernod.com/news/the-vision-council-releases-provider-insights-q1-2022-report/2480877/The Vision Council has released the Provider inSights Q1 2022 Report. The publication of the report continues the roll-out of The Vision Council’s new
- iSTAR Medical Expands Commercial Rollout With First MINIject Surgeries in Switzerlandhttps://modernod.com/news/istar-medical-expands-commercial-rollout-with-first-miniject-surgeries-in-switzerland/2480852/iSTAR Medical announced that it has continued its commercial rollout expansion for MINIject® to Switzerland. MINIject® is iSTAR Medical’s MIGS implant and currently the only commercially available supraciliary MIGS device, according to the company. Swiss patients with open-angl
- Tarsus Presents New Findings From Two Studies That Demonstrate the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meetinghttps://modernod.com/news/tarsus-presents-new-findings-from-two-studies-that-demonstrate-the-impact-of-demodex-blepharitis-at-the-arvo-2022-annual-meeting/2480847/Tarsus Pharmaceuticals, Inc. presented data from its Atlas Continuation study on the negative impact Demodex blepharitis has on daily life and visual function among certain patient groups, as well as preliminary findings from the Pandora study on the coexisting bacterial burden for patients with
- Skye Bioscience Reports Enhanced IOP-Lowering of SBI-100 Formulationhttps://modernod.com/news/skye-bioscience-reports-enhanced-iop-lowering-of-sbi-100-formulation/2480846/Skye Bioscience announced that the peer-reviewed journal International Journal of Pharmaceutics published preclinical data demonstrating stronger and longer-lasting reduction of IOP when Skye’s proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the
- CooperVision Seeks Proposals for 2022 Science and Technology Awardshttps://modernod.com/news/coopervision-seeks-proposals-for-2022-science-and-technology-awards/2480832/To promote continuous advancement in contact lens research and development, CooperVision is now accepting submissions for its 2022 Science and Technology Awards program. The longstanding program fosters partnerships between recipients and CooperVision scientists to explore new dimensions in visio
- Verana Health Report Shows a More Than 80% Glaucoma Surgery Uptake Over 8-Year Periodhttps://modernod.com/news/verana-health-unveils-annual-ophthalmic-industry-report-that-shows-a-more-than-80-glaucoma-surgery-uptake-over-8-year-period-1/2480818/Verana Health announced the release of its American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) Industry Report for 2021 at the ASCRS annual meeting. The report provides 8 years of detailed ophthalmic insights generated through analysis of the data contained i